MiNK Therapeutics(US:INKT) Globenewswireยท2025-11-14 12:30Core Insights - MiNK Therapeutics reported significant clinical advancements and financial results for Q3 2025, highlighting durable clinical responses with its lead asset, agenT-797, and the expansion of its iNKT platform across various therapeutic areas [1][4][6] Q3 2025 Highlights - Durable clinical responses were observed in refractory solid tumors with agenT-797, including complete remissions lasting over two years and survival rates exceeding two to three years in late-stage cancers [2] - The safety profile of agenT-797 was favorable, with no reported cases of Grade 3 cytokine release syndrome (CRS) or neurotoxicity [2] - MiNK initiated a collaboration with the University of Wisconsin Carbone Cancer Center for a preclinical and Phase 1 study of agenT-797 aimed at preventing graft-versus-host disease (GvHD) in stem-cell transplant patients [2][4] Leadership Strengthening - Dr. Terese C. Hammond joined as Head of Inflammatory and Pulmonary Diseases, focusing on late-stage programs for acute respiratory distress syndrome (ARDS) and GvHD [5] - Colonel (Ret.) John B. Holcomb was appointed to the Board of Directors, bringing expertise in trauma and critical care [5] Financial Highlights - As of September 30, 2025, MiNK had approximately $14.3 million in cash and cash equivalents, an increase from $4.6 million at the end of 2024 [9][14] - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share for Q3 2024 [11][14] - Cash used in operations for Q3 2025 was $941,000, a decrease from $2.995 million in Q3 2024 [11] Future Catalysts - MiNK plans to initiate multiple studies and expects early clinical readouts over the next 12 months, focusing on oncology, inflammatory diseases, and critical illness [12][13] - Key upcoming milestones include the initiation of the NIH-supported Phase 1 GvHD study and early data from a Phase 2 trial in severe pulmonary inflammatory disease [15]